Ramlau R, Quoix E, Rolski J, et al. A Phase II Study of Tg4010 ( Mva-Muc1 -Il2) in Association with Chemotherap y in Patients with Stage III/ IV Non -small Cell L ung Cancer. Journal of Thoracic Oncology . 2008;3(7):735 -44. 95. Ozturk M, L i Y, Tergaonkar V. Current Insights to Regulation and Role of Telomerase in Human Diseases. Antioxidants. 2017;6(1):17. 96. Qian Y, Yang L, Cao S. Telomeres and telomerase in T cells of tumor immunity . Cellular I mmunology . 2014;289(1- 2):63-9. 97. Gavazza A, L ubas G, Fridman A, et al. Safet y and Efficacy of a Genetic Vaccine Targeting Telomerase Plus Chem otherap y for the Therap y of Canine B -Cell Lym phoma. Human Gene Therapy . 2013;24(8):728-38. PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 13898. Bolonaki I, Kotsakis A, Papadimitraki E, et al. Vaccination of Patients With Advanced Non–Small -Cell L ung Cancer With an Optimized Cry ptic Human Telomerase Reverse Transcriptase Peptide. Journal of Clinical Oncology . 2007;25(19):2727 -34.